Resume

Sign in

Clinical Research Medical

Location:
United States
Posted:
February 28, 2019

Contact this candidate

Resume:

CURRICULUM VITAE

NAME

Robert H. Zeiler, PhD

**** *** ******* **

Watsonville, CA 95076

Phone (cell): 707-***-****

Email (home): ac8mzi@r.postjobfree.com

EDUCATION

1981

Doctor of Philosophy, Biology

New York University

Graduate School of Arts and Science

Washington Square

New York, New York, USA

Title of Thesis: The Electrophysiological and Contractile Responses of Canine Atrial Tissue to Adrenocorticotropin.

1973

Master of Science, Physiology

Long Island University

Flatbush Avenue Extension

Brooklyn, New York, USA

1971

Bachelor of Science, Biology

Long Island University

Flatbush Avenue Extension

Brooklyn, New York, USA

MEMBERSHIPS

1995 to Present

American Heart Association

2010 to Present

Society of Quality Assurance

WORK EXPERIENCE

2013 to 2014 Executive Vice Chair

Western Institutional Review Board (WIRB)

1019 39th Avenue

Puyallup, WA 98374

Lead and manage IRB Affairs section that includes all panel chairs and vice chairs.

Serve as voting panel member and consultant

Provide protocol scheduling of protocols for all panels

Provide training for new employees as well as new topics and protocol training for existing employees.

Design, plan and provide continuous improvement projects

August 2011 to December 2013 Vice President – Research,

Assistant Dean of Administration and Research

Associate Professor of Physiology

California Northstate University

College of Medicine

College of Pharmacy

Elk Grove, California 95757

Establish, organize and manage the university Office of Research

Administration of the Department of Medical Education and oversee/manage the College of Medicine research efforts. Includes budgetary and planning responsibilities.

Primary coordinator for courses in Physiology. Assist with other courses and coordination as needed.

Authored documents for LCME and WASC databases.

Responsible for strategic long- and short-term planning of Research Activities, including clinical trials and regulatory activities in the College of Medicine.

Chair, university Research Committee

Initiated and Chair College of Medicine Institutional Review Board

Initiated and Chair College of Medicine Research Committee

Chair, Basic Science Faculty Recruitment Committee

Member, Curriculum Committee

Member, Curricular Assessment and Evaluation Committee

Member, Admissions Committee

Member, Rank, Promotion and Retention Committee

Member, Student Promotion Committee

Member, Faculty Handbook Committee

Member, Self Study Committee (LCME)

November 2008 to August 2011 Associate Professor of Pharmaceutical Sciences

University of New England

College of Pharmacy

Portland, Maine 04103

Primary instructor for course in Pathophysiology. Assist with other courses as needed.

Primary instructor and creator for new course entitled “How New Drugs Get To Market”

Establish laboratory and conduct original research in cardiac electrophysiology and biophysics or related areas.

Responsible for strategic long- and short-term planning of Clinical Trial and Regulatory activities in the College of Pharmacy as well as coordination of these activities outside the University of New England, including GLP, GMP and GCP quality control.

Interprets and establishes policy, develops and implements strategies for the earliest possible approval of regulatory submission and reviews ongoing projects.

Chairman, Assessment and Evaluation Committee

Member, University Institutional Review Board

Member, University Research Committee

Member, Awards and Honors Committee

Member, Pharmacy Practice Committee

Member, Admissions Committee

Member, Faculty Handbook Committee

Member, Self Study Committee

Member, University of Southern Maine, Animal Research Review Committee

Editorial Board, Online Journal of Population Health

July 2007 to March 2008 Sr. Director, Clinical Operations & Regulatory

NeuroSystec Corp.

Valencia, California 91355

Responsible for strategic long- and short-term planning of Clinical and Regulatory activities in coordination with VP.

Interprets and establishes corporate policy, develops and implements strategies for the earliest possible approval of regulatory submission and reviews ongoing projects.

Design, plan, conduct, analyze and report on clinical research programs to evaluate and demonstrate the medical safety and efficacy of novel device/therapeutic agents combinations.

Provide scientific and clinical research expertise and guidance, clinical trial management expertise and direction to the staff.

Negotiates with outside agencies and key opinion leaders (national and international) as needed to resolve key clinical and regulatory issues.

Oversees the preparation and submission of applications and routine reports/renewals, including the preparation and submission of supplements and amendments as required by internal department (Manufacturing, QA/QC, Medical, etc.) to update registered product information.

Evaluates resources and equipment requirements for the clinical and regulatory areas to ensure the successful operations of clinical trials

Develops budget requirements, and monitors project and program costs.

Strategic development and authoring of clinical and regulatory processes. Identify problems and/or issues with processes and/or personnel.

Review and prepare responses to inquires from regulatory authorities relating to product registrations.

Participate in vendor capability and contract negotiation meetings.

Hire, train and develop clinical and regulatory staff and provide input on associated compensation and department structure decisions.

July 2006 to July 2007 Director, Cardiovascular Clinical Operations

PDL BioPharma

Fremont, California 94555

Manages all staff to successfully implement Clinical Operations goals. Ensures that clinical research activities are completed on or ahead of time and on budget.

Provides strategic input from a clinical operations perspective into clinical development plan and protocol design.

Supervises managers and support staff with responsibility for hiring, performance reviews, salary decisions and any performance-related issues.

Evaluates resources and equipment requirements for the clinical department to ensure the successful operations of clinical trials

Collaborates with other functional groups in support of clinical trials and corporate goals in particular with clinical development and Global Programs Management.

Ensures regulatory and legal integrity of all training processes, clinical research filing and clinical research management systems utilized within the clinical operations department.

Provides strategic direction to grow and develop the Clinical Operations group.

Oversees a significant portion of the clinical operations budget.

Identifies, recommends, implements and participates or leads cross-functional projects/initiatives as required to ensure continuing improvement of process at PDL.

Sep. 2003 to Dec. 2005 Director, Clinical Operations & Clinical Studies

Medtronic Vascular

Santa Rosa, California 95403

Responsible for planning and implementing policies, procedures, practices and strategy for the clinical research and clinical operations functions. Coordinate AOP and department planning to ensure that the Clinical Affairs department functions optimally and within the budget.

Established Clinical Operations Department consisting of Field Monitoring, Compliance and Documentation, Device Distribution, Payments, Contracts, Training and Safety sections interacting with all projects at Vascular (Drug Eluting Stent, Endovascular stent grafts and bare metal stents).

Work with sales and marketing to choose investigators and clinical sites. Direct and oversee interface with clinical investigators and institutional review boards, funding negotiations with clinical sites, contracts with hospitals, consultants, clinical investigators, contract research organizations and database management firms.

Ensure that Clinical Affairs department interfaces with key functional groups (R&D, Manufacturing, Sales, Marketing, Regulatory Affairs, and European Clinical Groups) to drive clinical wide or cross-departmental iniatives.

Work in collaboration with Director of Regulatory to prepare IDE, 510(k), PMA and related regulatory filings. Provide clinical interfaces with regulatory agencies as appropriate.

Coach Program, Project and Study Managers and other functional managers with all aspects of their responsibilities. Oversee the clinical department SOP/DOP review and development, employee training, and associated requirements.

Actively work to promote team building and morale within the department, assure project teams are appropriately resourced and strategically assess resource utilization.

Responsible for overall performance management of direct report personnel.

Member of Clinical Council representing Vascular at Corporate meetings.

Feb. 2002 to Jun. 2003 Senior Director, Clinical Operations

Ingenix

Basking Ridge, New Jersey, USA

Oversee the direction of project teams and project management personnel to ensure timely delivery of high quality project deliverables.

Interacts with sponsors and Directors, Clinical Projects to assure consistent performance and quality of work.

Assures project teams are appropriately resourced.

Strategically assesses resource utilization and makes changes.

Assures training requirements of personnel are met.

Interacts with other departments to identify problems and/or issues with personnel and/or processes across departments and works with associated department management in implementing processes to streamline the delivery of services to the client.

Responsible for overall performance management of personnel.

Supports Business Development in the strategic development of processes required for interaction with clinical operations.

Identifies new business opportunities and directs/assists with proposal generation.

Represents the project management function at customer audits.

2000 to 2002 Associate Director, Cardiopulmonary, Clinical Operations

Forest Laboratories

New York, New York, USA

Responsible for clinical development planning, placed and managed clinical studies. Delivered studies on time, within budget and with good quality data.

Developed detailed study/program implementation plans (resource/time/cost).

Responsible for the daily Clinical Operations functions for Phase II, III, IIIB and IV multi-center and single center trials or series of studies within a project.

Provided the strategic and tactical planning, organization, and direction within Clinical Operations to achieve the successful completion of studies within a project.

Provided scientific and clinical research expertise and guidance, clinical trial management expertise and direction to the Clinical Team.

Provided the Clinical Operations Sr. Director with regular status updates.

2000 Consultant

Schering-Plough

Kenilworth, New Jersey, USA

Provided scientific and clinical research expertise to analyze and report global and domestic clinical research data in the cardiovascular therapeutic area.

Designed, developed, and provided training for customized computerized tracking, monitoring, and data analysis schemes of CRF and safety data, allowing streamlining of procedures for current clinical studies.

Standardized, reviewed, edited and final summarization of drug safety data within the database as well as identifying and troubleshooting possible NDA problems.

Developed standard procedures allowing the scientific staff to recall and analyze comment forms required for adverse events.

1996 to 2000 Clinical Operations Manager/Global SMT Leader

Hoffmann-La-Roche

Nutley, New Jersey, USA

Responsible for the development of high-level resource estimates of Clinical Development plans.

Developed detailed study/program implementation plans, placing and managing clinical studies.

Provided high-quality data within the agreed upon parameters.

Responsible for the daily Clinical Operations functions for Phase III multi-center trials or series of studies within a project.

Delivered studies on time, within budget and with good quality.

Provided the strategic and tactical planning, organization and direction within Clinical Operations to achieve the successful completion of studies within a project.

Provided scientific and clinical research expertise and guidance, clinical trial management expertise and direction to the protocol implementation team.

Led the Study Management Team.

Provided the Project Account Leader with regular status updates regarding timelines, budgets, and quality.

Identified critical issues requiring higher lever team intervention.

1995 to 1996 Independent Consultant Scientist/CRA

Hoffmann-La Roche

Nutley, New Jersey, USA

Provided scientific and clinical research expertise in designing phase II protocols for new therapeutic agent with numerous indications.

Designed, developed and provided training for customized computerized tracking, monitoring, budgeting and data analysis schemes.

Standardized, reviewed, edited and provided summary of drug safety data within the database as well as identifying and troubleshooting possible NDA problems.

Developed standard procedures allowing the scientist staff to recall and analyze sponsor comment forms required for adverse events and marked laboratory abnormalities.

As Global ECG and Adverse Event Coding Officer Provided data reduction and subsequent database coding of all electrocardiographic data in numerous completed protocols.

1994 Independent Consultant Scientist

Schneider (USA), Inc.

Pfizer Hospital Products Group

Minneapolis, Minnesota, USA

Provided scientific and clinical research expertise in the design, plan, conduct, and data analysis of the new coronary wall stent project and Phase III protocol for subsequent FDA device approval.

Designed the project and reviewing suggestions from field experts in the global community.

Planned and coordinated the major multi-center investigator meeting.

1992 to 1994 Clinical Research Scientist II

Sandoz Pharmaceuticals Corporation

Medical Affairs/Clinical Operations

East Hanover, New Jersey, USA

Designed, planned, conducted, analyzed and reported clinical research programs to evaluate and demonstrate the medical safety and efficacy of therapeutic agents in the cardiovascular area.

Provided supervision, cardiovascular and clinical research expertise and training for junior clinical scientist and non-scientist staff.

Reviewed and reported data from completed clinical trials including investigator negotiations for possible publication of data in peer-reviewed journals.

Reviewed, updated, and approved cardiovascular related marketing promotional materials for scientific and medical accuracy.

Reviewed, updated and approved the medical services database literature.

Served as member on the following committees and teams:

Medical Affairs Protocol Review Committee

Medical Affairs Central File Committee

MIS Laptop Project Review Team

Promotional Clearance & Medical Services Team

DynaCirca® DYNAMICS & ISRAD Analysis Teams

DynaCirca® MIDAS and fluvastatin working groups

1988 to 1992 Senior Clinical Scientist, Assistant Manager

Wyeth-Ayerst Research

Radnor, Pennsylvania, USA

Designed, planned, conducted, analyzed, and reported clinical research programs to evaluate and demonstrate the medical safety and efficacy of new therapeutic agent in the cardiovascular area.

Designed and initiated clinical drug trials and monitored their programs.

Provided supervision, expertise, and training for more junior clinical scientist and non-scientific staff.

Reviewed and reported data from completed clinical trials.

Acted as Chairman of the Pro-arrhythmia and Drug Data Committees.

1987 to 1988 Senior Assistant Clinical Scientist - Cardiovascular Section

Warner-Lambert/Parke-Davis

Pharmaceutical Research Division

Ann Arbor, Michigan, USA

Designed, planned, conducted, and reported clinical research programs to evaluate and demonstrate the medical safety and efficacy of new therapeutic agents in cardiovascular.

Designed and initiated clinical trials, and monitored the progress.

Reviewed data and prepared final reports for Food and Drug Administration submissions.

1978 to 1987 Acting Administrative Officer, Medical Service

Supervisory Cardiac Physiologist

Assistant Professor Medicine and Physiology -

SUNY Downstate Medical Center

Brooklyn V.A. Medical

Department of Cardiology

Brooklyn, New York, USA

Responsible for administration and technical activities of the Medical Service and the Cardiology Section.

Supervised the cardiology laboratories and testing services including the Clinical Electrophysiology Laboratory, Intensive Care Units Procedure Room and Pacemaker Laboratory, Stress Treadmill and Bicycle Ergometer Exercise Testing and Conditioning Laboratory, Phonocardiography and external pulse recording echocardiography Laboratory, Myocardial Metabolism Studies, the In Vivo and In Vitro Electrophysiology Research laboratories, and investigative clinical drug trials for various pharmaceutical companies.

Supervised electrocardiograph technicians, echocardiograph and electrophysiology technicians as well as project direction of professional staff.

Developed new invasive and non-invasive cardiovascular procedures including external HIS bundle recording, sinus node, and pre-and post-atrial activity studies.

Created, developed, and maintained computerized database programs used for reporting Echocardiography, Holter Monitoring, and Pacemaker results.

Initiated orders and maintained cost centers for cardiology department and laboratories.

Supervised and instructed employees in invasive electrophysiology techniques.

Responsible for the use, maintenance and calibration of highly complex electrical and electronic equipment.

Acted in Chairman of the Microcomputer Sub-committee.

1976 to 1978 Technical Specialist

State University of New York

Downstate Medical Center

Brooklyn, New York, USA

Performed research in electrophysiology and muscle physiology involving laboratory animal operative procedures and the utilization of microelectrode and voltage clamp techniques.

Managed the Laboratory.

Maintained and calibrated laboratory equipment.

Technical consultant for the clinical electrophysiology laboratory.

1974 to 1976 Research Technologist

State University of New York

Downstate Medical Center

Brooklyn, New York, USA

Research into automated cytology.

Research into adapting color television to endoscopic procedures.

1973 to 1974 Clinical Laboratory Technologist

Brooklyn-Cumberland medical Center

Department of Chemistry

Brooklyn, New York, USA

Clinical Research and development of Atomic Absorption Spectrophotometer techniques for the determination of metals in physiological systems.

Research and development into the application of computer systems to the analysis of clinical chemistries.

1972 to 1973 Laboratory Technologist, Chemistry

Brooklyn V.A. Medical Center

Department of Chemistry

Brooklyn, New York, USA

Responsible for manual and automated clinical chemistries.

1971 to 1972 Head of Hematology Section

Manhattan Clinical and Pathological Labs

New York, New York, USA

Responsible for clinical and special hematology.

1970 to 1971 Laboratory Technologist

Bellevue Hospital Center

Department of Hematology

New York, New York, USA

Responsible for routine clinical and special hematological assays and phlebotomy teams.

PUBLICATIONS AND PRESENTATIONS

1. Gelles JM and Zeiler RH: "ELECTRO-MECHANICAL COUPLING IN CARDIAC MUSCLE; EFFECTS OF CALCIUM IONOPHORES." Circulation, 55 and 66: III-46, 1977.

2. Gelles JM and Zeiler RH: "IS NA-CA EXCHANGE IN CARDIAC PURKINJE FIBERS ELECTROGENIC?." Fed. Proceedings, 37:3, 1987, 1978.

3. Zeiler RH, Gelles JM, and Krasnow N: "THE EFFECTS OF NATURAL AND SYNTHETIC IONOPHORES ON THE ACTION POTENTIAL AND ISOMETRIC CONTRACTION OF CARDIAC PURKINJE FIBERS." Fed. Proceedings, 37.3, 1898, 1978.

4. Gelles JM, Zeiler RH, and Krasnow N: "ELECTRO-MECHANICAL COUPLING IN CARDIAC PURKINJE FIBERS: EFFECTS OF IONOPHORE X-537A." Bull. N.Y. Aced. Med. 54-3: 316-317, 1978.

5. Gelles JM and Zeiler RH: "ELECTROGENIC HYPERPOLARIZATION IN CANINE CARDIAC PURKINJE FIBERS EXPOSED TO CALCIUM IONOPHORES." Experientia 34:619, 1978.

6. El-Sherif N, Gomes JAC, Kelen GJ, Khan RG, Kang PS, and Zeiler RH: "ELECTROPHYSIOLOGIC, BIOCHEMICAL AND PHARMACOLOGICAL ASPECTS OF REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD. "IN: "SUDDEN DEATH."

7. El-Sherif N, Gomes JAC, Kelen GJ, Khan RG Kang PS, and Zeiler RH: "ELECTROPHYSIOLOGY OF REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD." In: "New Trends in Medical and Surgical Management of Tachyarrhythmias." Editors, L. Seipl, H.D. Schulti. 1980.

8. El-Sherif N, Zeiler RH, Gough W: "EFFECTS OF CATECHOLAMINES, VERAPAMIL AND TETRODOTOXIN ON TRIGGERED AUTOMATICITY IN CANINE ISCHEMIC PURKINJE FIBERS." Circulation 62: Suppl. III; 1076, 1980.

9.Zeiler RH, Gough WB, Sung R, El-Sherif N: "ELECTROPHYSIOLOGIC EFFECT OF PROPAFENONE IN CANINE ISCHEMIC CARDIAC CELLS." Am. J. Cardiol, 47:483, 1981.

10.El-Sherif N, Gough, WB, Zeiler RH, Mehra R: "EPICARDIAL MAPPING OF TRIGGERED

AUTOMATICITY IN CANINE ISCHEMIC PURKINJE FIBERS." Am. J. Cardiol., 47:489, 1981.

11. Gough WB, Zeiler RH, El-Sherif N: "THE ANTIARRHYTHMIC ACTION OF NIFEDIPINE ON TRIGGERED ACTIVITY IN ONE DAY OLD ISCHEMIC ENDOCARDIUM." Circulation 64: Suppl. IV; 274, 1981.

12. El-Sherif N, Gough WB, Zeiler RH, Mehra R: "DIFFERENT MECHANISMS FOR SPONTANEOUS AND INDUCED VENTRICULAR RHYTHMS IN 24 HOUR-OLD MYOCARDIAL INFARCTION IN THE DOG." Circulation 64: Suppl. IV; 218, 1981.

13. Mehra R, Zeiler RH, Gough WB, El-Sherif N: "MECHANISM OF REPETITIVE VENTRICULAR RESPONSES RVR'S BLOCK." Circulation 64: Suppl. IV; 172, 1981.

14. Gough WB, Zeiler RH, Barreca P, El-Sherif N: "THE HYPOTENSIVE EFFECTS OF COMMERCIAL INTRAVENOUS AMIODARONE IN DOGS: DEPENDENCE ON THE DILUENT POLYSORBATE 80." J. of Cardiovascular Pharm., 4:375-380, 1982.

15. Mehra R, Kelen GJ, Zeiler RH, Zephiran D, Fried P, Gomes JA, El-Sherif N: "NON-INVASIVE HIS BUNDLE ELECTROGRAM: VALUE OF THREE VECTOR LEAD RECORDINGS." Am. J. Cardiol., 49:344-348, 1982.

16. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "VENTRICULAR RHYTHMS IN CANINE ONE-DAY-OLD MYOCARDIAL INFARCTION. EVIDENCE FOR FOCAL AND REENTRANT MECHANISMS." Circulation Research, 51:152-166, 1982.

17. Mehra R, Zeiler RH, Gough WB, El-Sherif N: "REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD. 9. ELECTROPHYSIOLOGICAL ANATOMICAL CORRELATION OF REENTRANT CIRCUITS." Circulation. 67(1):11-24, January, 1983.

18. Gough WB, Zeiler RH, El-Sherif N: "EFFECTS OF CALCIUM AND CALCIUM ANTAGONISTS ON TRIGGERED ACTIVITY IN ONE-DAY-OLD CANINE ISCHEMIC ENDOCARDIUM." Am J. Cardiol., 49:914, 1982.

19. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "MECHANISM OF REENTRANT RHYTHMS INDUCED BY BURSTS OF RAPID VENTRICULAR STIMULATION IN THE ISCHEMIC CANINE HEART." Am J. Cardiol., 49:934, 1982.

20. Zeiler RH, Strand FL, El-Sherif N: "CANINE LEFT ATRIAL TISSUE SPECIFICALLY BINDS ADRENOCORTICOTROPIC HORMONE." Am. J. Cardiol., 49:1037, 1982.

21. Zeiler RH, Strand FL, El-Sherif N: "ELECTROPHYSIOLOGICAL AND CONTRACTILE RESPONSES OF CANINE ATRIAL TISSUE TO ADRENOCORTICOTROPIN." Peptides, 3:815, 1982.

22. Zeiler RH, Gough WB, El-Sherif N: "ROLE OF CA2+ AND NA2+ ON AFTER DEPOLARIZATIONS IN CANINE ISCHEMIC PURKINJE FIBERS." Circulation, 66:II-78, 1982.

23. Gough WB, Zeiler RH, El-Sherif N: "BASIS FOR REDUCED TRANSMEMBRANE POTENTIALS ASSORTED WITH TRIGGERED ACTIVITY IN ISCHEMIC SUBENDOCARDIAL PURKINJE FIBERS." Circulation, 66:II-156, 1982.

24. Hariman RJ, Zeiler RH, Gough WB, El-Sherif N: "THE EFFECT OF OUABAIN ON TRIGGERED ACTIVITY IN ONE DAY ONE CANINE INFARCTION.: Circulation, 66:II, 1982.

25. El-Sherif N, Gough WB, Zeiler RH, Mehra R: "VENTRICULAR RHYTHMS IN ONE-DAY-OLD CANINE INFARCTION ARE DUE TO TRIGGERED ACTIVITY." Circulation, 66:II-357, 1982.

26. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "TERMINATION OF REENTRANT CIRCUITS IN CANINE INFARCTION BY CRYOTHERMAL TECHNIQUES." Circulation, 66:II-358, 1982.

27. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "VENTRICULAR ACTIVATION PATTERNS OF SPONTANEOUS AND INDUCED VENTRICULAR RHYTHMS IN CANINE ONE-DAY-OLD MYOCARDIAL INFARCTION." Circulation Research, 51:152-166, 1982.

28. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "VENTRICULAR ACTIVATION PATTERNS OF PLEOMORPHIC VENTRICULAR TACHYCARDIAS THAT TERMINATE SPONTANEOUSLY OR DEGENERATE INTO VENTRICULAR FIBRILLATION." J. American College of Cardiology, 2:621, 1983.

29. Gough WB, Zeiler RH, El-Sherif N: "EFFECTS OF DILTIAZEM ON TRIGGERED ACTIVITY IN ONE-DAY-OLD ISCHEMIC ENDOCARDIUM OF THE DOG." J. American College of Cardiology, 2:692, 1983.

30. Mehra E, Zeiler RH, Gough WB, El-Sherif N: "REENTRANT VENTRICULAR ARRHYTHMIAS CORRELATION OF REENTRANT CIRCUITS. THE ANATOMICAL BASIS FOR REENTRY." Circulation 67(1):11-24, 1983.

31. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "EFFECTS OF REVERSIBLE COOLING ON REENTRANT TACHYCARDIA IN CANINE INFARCTION." Pace, 6:5, 1983.

32. El-Sherif N, Gough WB, Zeiler RH, Mehra R: "TRIGGERED RHYTHMS IN ONE-DAY-OLD MYOCARDIAL INFARCTION IN THE DOG." Circulation Research, 52:566-579, 1983.

33. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD AND INTERRUPTION OF REENTRANT CIRCUITS BY CRYOTHERMAL TECHNIQUES." Circulation, 63:644-656, 1983.

34. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "EFFECTS OF REVERSIBLE COOLING ON REENTRANT TACHYCARDIAS IN CANINE INFARCTION." Physiologist 26:A91, 1983.

35. Gough WB, Zeiler RH, El-Sherif N: "EFFECTS OF CAFFEINE ON TRIGGERED ACTIVITY IN ONE-DAY-OLD ISCHEMIC ENDOCARDIUM OF THE DOG." Circulation 68:III-20, 1983.

36. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "BURST PACING VERSUS PREMATURE STIMULATION IN THE INDUCTION OF REENTRY." J. Amer. Coll. Cardiol. 3:587, 1984.

37. Mehra R, Gough WB, Zeiler RH, El-Sherif N: "MECHANISM OF LIDOCAINE ACTION ON REENTRANT VENTRICULAR RHYTHMS IN THE CANINE ISCHEMIC HEART." J. Amer. Coll. Cardiol. 3:542, 1984.

38. Gough WB, Zeiler RH, El-Sherif N: "EFFECTS OF NIFEDIPINE ON TRIGGERED ACTIVITY IN ONE-DAY-OLD MYOCARDIAL INFARCTION IN DOGS." Amer. J. Cardiol. 53:303-306, 1984.

39. Mehra R, Gough WB, Zeiler RH, El-Sherif N: "DUAL VENTRICULAR STIMULATION FOR PREVENTION OF REENTRANT VENTRICULAR ARRHYTHMIAS." J. Amer. Coll. Cardiol. 3:472, 1984.

40. Gough WB, Zeiler RH, El-Sherif N: "DEPENDENCE OF TRIGGERED ACTIVITY ON DIASTOLIC POTENTIALS IN ONE-DAY-OLD ISCHEMIC PURKINJE FIBERS." J. Amer. Coll. Cardiol. 3:477, 1984.

41. El-Sherif N, Gough WB, Zeiler RH: "THE EFFECT OF DIFFERENTIAL SHORTENING OF REFRACTORINESS IN SUCCESSIVE SHORT CARDIAC CYCLES ON THE INITIATION AND TERMINATION OF REENTRY IN THE ISCHEMIC CANINE HEART." J. Amer. Coll. Cardiol. 3:477, 1984.

42. Zeiler RH, Gough WB, El-Sherif N: "ELECTROPHYSIOLOGIC EFFECT OF PROPAFENONE ON CANINE ISCHEMIC CARDIAC CELLS." Amer. J. Cardiol. 54:424-429, 1984.

43. El-Sherif N, Mehra R, Gough WB, Zeiler RH: "REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD: II. BURST PACING VERSUS MULTIPLE PREMATURE STIMULATION IN THE INDUCTION OF REENTRY." J. Amer. Coll. Cardiol. 4:295-304, 1984.

44. Zeiler RH, Tobiasz C, Henkin R, Gough WB, El-Sherif N: "THE EFFECTS OF ISCHEMIA ON INTRACELLULAR POTASSIUM ACTIVITY AND MEMBRANE POTENTIAL IN CANINE ENDOCARDIAL TISSUE." Circulation, 70(4): 898, 1984.

45. Gough WB, Zeiler RH, El-Sherif N: "EFFECTS OF DILTIAZEM ON TRIGGERED ACTIVITY IN CANINE ONE-DAY-OLD INFARCTION. Cardiovasc Res 18:339-343, 1984.

46. El-Sherif N, Gough WB, Hariman R, Zeiler RH: "MECHANISMS OF TERMINATION OF ACCELERATION OF REENTRANT TACHYCARDIA BY BURST PACING." Circulation, 70:II-91, 1984.

47. Hariman RH, Zeiler RH, Gough WB, El-Sherif N: "ENHANCEMENT OF TRIGGERED ACTIVITY IN ISCHEMIC PURKINJE FIBERS BY OUABAIN. A MECHANISM OF INCREASED SUSCEPTIBILITY TO DIGITALIS TOXICITY IN MYOCARDIAL INFARCTION." J. Amer. Coll. Card. 5(3):672-679, 1985.

48. El-Sherif N, Gough WB, Hariman R, Zeiler RH: "ROLE OF NON UNIFORM REFRACTORY DISTRIBUTION VERSUS ANISOTROPIC ANATOMIC PROPERTIES IN THE INITIATION OF REENTRANT EXCITATION IN THE CANINE POST-INFARCTION HEART." J. Amer. Coll. Card. 5:390, 1985.

49.El-Sherif N, Gough WB, Zeiler RH, and Hariman R: "REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD. 12. SPONTANEOUS VERSUS INDUCED REENTRY AND INTRAMURAL VERSUS EPICARDIAL CIRCUITS. J. Am. Coll. Cardiol. 6(1):124-132, 1985.

50. Gough WB, Mehra R, Restive M, Zeiler RH and El-Sherif N: "REENTRANT VENTRICULAR ARRHYTHMIAS IN THE LATE MYOCARDIAL INFARCTION PERIOD IN DOG. 13. CORRELATION OF ACTIVATION AND REFRACTORY MAPS." Circ. Res. 57(3):432-442, 1985.

51. El-Sherif N, Gough WB, Zeiler RH, Craelius W, and Restivo M: "ROLE OF NON UNIFORM REFRACTORY DISTRIBUTION VERSUS ANISOTROPIC PROPERTIES IN THE INITIATION OF REENTRANT EXCITATION IN THE CANINE POST INFARCTION HEART." J. Amer. Coll. Cardiol. 5(2):390, 1985.

52. Fontaine JM, Zeiler RH, Henkin R, El-Sherif N: "SIMULTANEOUS MONOPHASIC ACTION POTENTIAL RECORDING AND REGIONAL ENDOCARDIAL REFRACTORY PERIOD DETERMINATION USING A NEW DUAL PURPOSE CONTACT ELECTRODE CATHETER., PACE 9(2):278, 1986.

53. Craelius W, Chen V, El-Sherif N, and Zeiler RH: "IN VIVO RECORDING OF EARLY AFTER DEPOLARIZATION PRECEDING TORSADES DE POINTES." J. Amer. Coll. Cardiol. 7:124A, 1986.

54. Kelen GJ, Henkin R, Restivo M, Zeiler RH, Caref EB, and El-Sherif N: "SIGNAL AVERAGING OF HIGH VAIN HOLTER EKG RECORDINGS VALIDATION OF A NEW TECHNIQUE



Contact this candidate